Table 2 Primary endpoint outcomes: MWT changes from baseline in Study 1 and Study 2
Group | Study 1 | Study 2 | |||||
|---|---|---|---|---|---|---|---|
Enerisant 25 mg | Enerisant 50 mg | Enerisant 100 mg | Placebo | Enerisant 5 mg | Enerisant 10 mg | Placebo | |
(n = 4) | (n = 10) | (n = 7) | (n = 11) | (n = 14) | (n = 18) | (n = 16) | |
SL at baseline (min) | 2.12 ± 1.77 | 3.22 ± 2.45 | 2.46 ± 1.54 | 2.64 ± 2.06 | 5.40 ± 3.04 | 5.08 ± 2.49 | 4.56 ± 3.24 |
SL at week 3 (min) | 3.50 ± 4.69 | 3.80 ± 4.52 | 2.53 ± 1.85 | 1.65 ± 1.98 | 5.43 ± 4.41 | 5.74 ± 4.73 | 4.84 ± 5.20 |
Change from baseline to week 3 (min) | 0.53 ± 2.75 | 0.33 ± 3.72 | − 0.16 ± 2.73 | − 0.88 ± 2.40 | 0.73 ± 3.42 | 0.66 ± 3.44 | 0.22 ± 4.90 |
Difference compared with placebo [95% CI] | 1.54 [− 2.00, − 5.08] | 1.50 [− 1.19, − 4.18] | 0.77 [− 2.16, − 3.70] | - | 0.43 [− 2.45, − 3.31] | 0.41 [− 2.30, − 3.13] | – |
p value | 0.380 | 0.263 | 0.594 | 0.765 | 0.761 | ||